Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded…
VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company…
Rising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service ExpansionComprehensive CDMO services now featured on Biomerica’s updated website…
FLORHAM PARK, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused…
Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering,…
- Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial…
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced…
Exclusive collaboration and license agreement focuses on advancing novel T cell therapy “Seed-and-Boost” approach exploiting the mechanism of the CUE-100…
Society for Neuroscience Annual Meeting, November 15-19, San Diego, CAWALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sironax, a global…
SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical…